Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation.
Therapeutic conclusions for staphylococcal implant infections treated with debridement and implant retention can only be drawn from a small series. To this aim, data from patients with implant staphylococcal infections (1998-2006) treated with debridement and implant retention were retrospectively reviewed. Infections were defined by staphylococci isolation (two or more consecutive debridement or three sinus tract discharge samples) along with clinical criteria. Patients received oral levofloxacin plus rifampicin for >or=6 weeks after the resolution of signs/symptoms and C-reactive protein normalisation. Failure was defined as lack of response or recurrence of signs/symptoms and/or sinus tract bacterial isolation during therapy or follow-up and/or implant removal. Twenty-five patients (53.2+/-20.8 years; 48% males) were included, 12 with spinal infections and 13 with limb implant infections. Diagnosis was performed from debridement material (72%) and sinus tract discharge (28%) (11 Staphylococcus aureus and 14 coagulase-negative staphylococci (CoNS)). Time from surgery to symptom onset was higher in CoNS infections compared with S. aureus infections (21.6+/-9.3 days vs. 12.6+/-5.2 days; P=0.007). Seven patients (28%) were failures, with no differences between cured patients with respect to age, sex, infection site, time from surgery to symptom onset, sinus tract diagnosis and aetiology. Longer symptom duration prior to attendance was observed in failures (5.7+/-6.2 months vs. 1.4+/-0.6 months; P=0.04). Levofloxacin plus rifampicin showed efficacy in implant infections, which was higher for short duration of symptoms.
Barberán
José
J
Infectious Diseases Department, Hospital Central de la Defensa Gómez Ulla, Gta. del Ejército s/n, Madrid, Spain.
Aguilar
Lorenzo
L
Giménez
María-José
MJ
Carroquino
Guillermo
G
Granizo
Juan-Jose
JJ
Prieto
José
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003030:Coagulase / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D009984:Orthopedic Fixation Devices / Q000009:adverse effects*; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000201:enzymology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D003030:Coagulase; D064704:Levofloxacin; D015242:Ofloxacin; D012293:Rifampin